Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dendrimer-TTM020
- Development stage
- Preclinical
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Parenteral
01
Overview
Dendrimer-TTM020 (D-TTM020) is an investigational nanoparticle polymer-drug conjugate consisting of the glutamine antagonist and 6-diazo-5-oxo-L-norleucine (DON) prodrug, TTM020, covalently linked to a hydroxyl-terminated poly(amidoamine) (PAMAM) dendrimer. Co-developed by researchers at Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), Dendrimer-TTM020 is designed to selectively target activated microglia in the central nervous system. Upon systemic administration, the dendrimer carrier crosses the blood-brain barrier and is selectively engulfed by inflamed microglia, where it releases the active glutamine antagonist to inhibit glutaminase (GLS1) activity. This localized mechanism of action mitigates the severe gastrointestinal and systemic toxicities typically associated with free glutamine antagonists. Dendrimer-TTM020 is currently in preclinical development for the treatment of neurodevelopmental and neuropsychiatric disorders, including Rett syndrome and chronic stress-induced depression.
- Other names
- dendrimer-TTM020dendrimer-TTM-020dendrimer-TTM 020
Beyond the preview
Go deeper on Dendrimer-TTM020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendrimer-TTM020.